多癌種檢測市場－全球產業規模、佔有率、趨勢、機會和預測：按檢測類型、技術、樣本類型、方法、癌症類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球多癌症篩檢市場預計將從 2025 年的 17.3 億美元大幅成長至 2031 年的 40.6 億美元，複合年成長率為 15.28%。

多癌種早期檢測 (MCED) 產品是推動這一成長的主要動力。這些診斷工具利用液態生物檢體技術，只需一份血液樣本即可識別多種惡性腫瘤的生物訊號，例如循環腫瘤 DNA。推動該市場發展的關鍵因素包括全球癌症發生率的上升以及預防醫學的廣泛轉變，後者強調非侵入性診斷。這些檢測在檢測目前尚無成熟篩檢方案的高侵襲性癌症方面具有顯著優勢，因此對於旨在減少晚期癌症診斷的醫療系統而言，它們是一種極具價值的解決方案。美國癌症協會估計，到 2025 年，美國將新增約 2,041,910 例癌症病例，凸顯了對這些工具的迫切需求。然而，獲得健保報銷是該市場面臨的主要障礙，因為保險公司通常會在獲得確鑿的縱向數據證明死亡率降低後才會做出承保決定。

市場促進因素

全球多癌種篩檢市場正因液態生物檢體和次世代定序技術的進步而發生根本性重塑。這些技術能夠精準檢測循環腫瘤DNA和甲基化模式，從而提示早期癌症。這些技術進步使得從單一血液樣本中同時識別多種癌症類型的訊號成為可能，顯著拓展了診斷能力，超越了傳統的單一適應症篩檢。這些先進平台的臨床有效性正日益得到可靠的性能數據支持，而這些數據對於它們的廣泛應用至關重要。例如，GRAIL於2025年10月發布的「PATHFINDER 2研究更新」顯示，將Galleri檢測納入標準篩檢流程，可使癌症檢出率比單獨進行標準篩檢提高七倍以上。這凸顯了液態生物檢體在滿足目前迫切需要一種工具來識別致命癌症方面的有效性，因為目前針對這些癌症尚無標準篩檢方案。生物技術領域的策略聯盟和夥伴關係正在進一步加速市場成長。診斷公司正與技術和製藥行業的領導企業合作，以獲得資金籌措並增強商業性擴充性。這些合作關係提供了必要的資金和營運支持，使企業能夠應對複雜的監管流程，並擴大多癌症種早期檢測 (MCED) 測試的覆蓋範圍。三星於 2025 年 11 月向 GRAIL 投資 1.1 億美元股權，旨在支持其研發和商業化，這就是這一趨勢的典型例證。 GRAIL 在 2025 年第三季財報中披露了這筆投資。整個篩檢產業的巨大財力，正如 Exact Sciences 在 2025 年第三季 8.51 億美元的營收所體現的那樣，為這些技術進步提供了充足的資源，並為未來的多癌種解決方案奠定了堅實的商業性基礎。

市場挑戰

全球多癌症篩檢市場商業性擴張的一大障礙是，保險公司嚴格要求提供長期死亡率數據以確保報銷。保險公司通常會延遲保險覆蓋範圍的決定，直到多癌早期檢測（MCED）的臨床效用得到最終證實。這意味著大多數患者仍需自費進行這些檢測。由於缺乏支付方的支持，市場僅限於特定富裕人群，阻礙了實現收入成長和規模經濟所需的廣泛普及。如果無法獲得標準的保險覆蓋，這些診斷工具就無法從可有可無的奢侈品轉變為公共衛生管理的基本要素。患者對篩檢方案的依從性問題進一步加劇了此經濟障礙的負面影響。例如，美國預防癌症基金會的報告指出，到2025年，只有51%的美國成年人會完成常規癌症篩檢，較前一年大幅下降。這項數據表明，即使是成熟且經常被納入保險範圍的檢測，患者的參與度仍然很低。因此，由於缺乏對新型且昂貴的 MCED 測試的保險報銷，幾乎肯定會導致公眾的採用率極低，直接阻礙市場發展。

市場趨勢

人工智慧 (AI) 和深度學習在生物標記發現領域的應用正在改變市場格局，顯著提升早期惡性腫瘤檢測的敏感度。這些先進的演算法平台能夠分析複雜的片段化模式和甲基化特徵，超越傳統的單突變檢測，精準區分真正的腫瘤訊號與背景體細胞雜訊。這項技術進步對於檢測低脫落率癌症至關重要，因為這類癌症難以透過標準液態生物檢體方法檢測。例如，2025 年 5 月，Harbinger Health 公司報告稱，其人工智慧驅動的平台在高風險族群中對早期癌症的檢測靈敏度達到 25.8%，特異性達到 98.3%，證實了機器學習能夠提升檢測準確性。一項重要的商業性趨勢是將多癌症種篩檢納入企業健康計劃，這項策略旨在規避現有的報銷難題。診斷技術開發公司正擴大繞過傳統的保險公司管道，直接與採用自保模式的雇主和人壽保險公司合作，將MCED檢測定位為對員工留任和預防性醫療保健至關重要的健康福利。這種B2B模式能夠即時產生收入，並累積真實世界的證據，即便全面的保險政策仍在製定之中。這種推廣管道的經濟效益顯而易見。 GRAIL在2025年11月發布的報告顯示，Galleri的銷售額達到3,280萬美元，較去年同期成長29%。這主要得益於商業夥伴關係的拓展和企業採用率的提升。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球多癌種檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依檢測類型（實驗室自建檢測 (LDT)、體外診斷醫療器材 (IVD)）
  • 依技術（次世代定序(NGS)、聚合酵素鏈鎖反應(PCR)、免疫組織化學 (IHC)、螢光雜合反應(FISH) 等）
  • 檢體類型（組織、血液、唾液和口腔黏膜拭子、其他）
  • 依方法（DNA、RNA、蛋白質）
  • 癌症類型（乳癌/婦科癌症、消化系統癌症、內分泌系統癌症、泌尿生殖系統癌症、皮膚癌、腦部/神經系統癌症、肉瘤、骨髓惡性腫瘤、肺癌、頭頸癌、其他癌症）
  • 按應用領域（臨床、研究）
  • 依最終使用者（醫院、診斷/臨床檢查室、學術研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美多癌症種檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲多癌種檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區多癌種檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲多癌種檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲多癌種檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球多癌症種檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Konica Minolta, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global multicancer screening market is anticipated to expand significantly, from USD 1.73 billion in 2025 to USD 4.06 billion by 2031, demonstrating a compound annual growth rate of 15.28%. This growth is driven by multicancer early detection (MCED) products, which are diagnostic tools employing liquid biopsy technology to identify biological signals, like circulating tumor DNA, from various types of malignancies using a single blood sample. Key factors propelling this market include the increasing global incidence of cancer and a broader shift towards preventive healthcare that emphasizes non-invasive diagnostic methods. These assays offer a distinct advantage by detecting aggressive cancers that currently lack established screening protocols, thereby offering a valuable solution for healthcare systems aiming to reduce late-stage diagnoses.The urgent demand for these tools is underscored by projections such as the American Cancer Society's estimate of approximately 2,041,910 new cancer cases in the United States in 2025. However, a significant obstacle for the market is securing reimbursement, as insurers typically postpone coverage decisions until definitive longitudinal data proves a reduction in mortality rates.

Market Driver

The global multicancer screening market is being fundamentally reshaped by advancements in liquid biopsy and next-generation sequencing, which enable the precise detection of circulating tumor DNA and methylation patterns indicative of early-stage cancers. These technological enhancements facilitate the simultaneous identification of signals from multiple cancer types from a single blood draw, thereby significantly broadening diagnostic capabilities beyond conventional single-indication screenings. The clinical effectiveness of these sophisticated platforms is increasingly validated by robust performance data, which is crucial for their widespread adoption. For example, a GRAIL study in October 2025, the 'PATHFINDER 2 Study Update', showed that incorporating the Galleri test into standard-of-care screenings led to over a seven-fold increase in cancer detection compared to standard screening alone, highlighting liquid biopsy's efficacy in addressing the critical need for tools to identify lethal cancers currently lacking standard screening protocols.Market growth is further accelerated by strategic collaborations and partnerships within the biotechnology sector, where diagnostic companies are partnering with technology and pharmaceutical leaders to secure funding and enhance commercial scalability. These alliances provide essential capital and operational support, enabling companies to navigate complex regulatory processes and expand the distribution of multicancer early detection (MCED) tests. An illustrative instance of this trend is Samsung's $110 million equity investment in GRAIL in November 2025, as reported in GRAIL's 'Third Quarter 2025 Financial Results', aimed at supporting development and commercialization. The substantial financial capacity of the wider screening sector, evidenced by Exact Sciences' $851 million revenue in the third quarter of 2025, also underscores the significant resources available for these advancements and the strong commercial foundation for future multi-cancer solutions.

Market Challenge

A significant barrier to the commercial scalability of the global multicancer screening market is the strict requirement for longitudinal mortality data to secure reimbursement. Insurers typically defer coverage decisions until the clinical utility of multicancer early detection (MCED) tests is conclusively demonstrated, which means these tests largely remain out-of-pocket expenses for most patients. This lack of payer support confines the market to a specialized segment of affluent individuals, thereby hindering the widespread adoption necessary for revenue growth and achieving economies of scale. Without a clear path to standard insurance coverage, these diagnostic tools cannot evolve from optional luxury items into fundamental elements of population health management.The adverse effects of this financial hurdle are exacerbated by existing challenges in maintaining patient adherence to screening protocols. For instance, the Prevent Cancer Foundation reported that in 2025, only 51% of U.S. adults completed their routine cancer screenings, representing a notable decrease from the prior year. This statistic underscores the already fragile nature of patient engagement, even for well-established and frequently covered procedures. Consequently, the absence of reimbursement for novel, expensive MCED assays will almost certainly lead to minimal adoption rates among the general populace, directly impeding the market's progression.

Market Trends

The market is being revolutionized by the integration of Artificial Intelligence and Deep Learning for biomarker discovery, which significantly boosts the sensitivity of assays for early-stage malignancies. These sophisticated algorithmic platforms go beyond traditional single-variant detection by analyzing intricate fragmentation patterns and methylation signatures to precisely differentiate authentic tumor-derived signals from background somatic noise. This technological advancement is crucial for detecting cancers with low shedding rates, which frequently elude standard liquid biopsy methods. For instance, Harbinger Health reported in May 2025 that its AI-enabled platform achieved 25.8% sensitivity for early-stage cancers at 98.3% specificity within a high-risk population, confirming machine learning's capacity to enhance detection accuracy.A key commercial shift involves integrating multicancer screening into corporate wellness programs, a strategy designed to circumvent existing reimbursement challenges. Diagnostic developers are increasingly bypassing conventional payer channels by directly collaborating with self-insured employers and life insurance providers, positioning MCED tests as valuable health benefits for employee retention and preventive care. This business-to-business approach generates immediate revenue streams and accumulates real-world evidence while comprehensive insurance coverage policies are still being developed. The financial effectiveness of this adoption channel is clear, as GRAIL reported in November 2025 that Galleri revenue grew 29% year-over-year to $32.8 million, primarily driven by expanded commercial partnerships and employer adoption.

Key Market Players

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Konica Minolta, Inc.

Report Scope

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multicancer Screening Market, By Test Type

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Multicancer Screening Market, By Sample

• Tissue
• Blood
• Saliva and Buccal Swab
• Others

Multicancer Screening Market, By Method

• DNA
• RNA
• Proteins

Multicancer Screening Market, By Cancer Type

• Breast and Gynecologic
• Gastrointestinal
• Endocrine
• Genitourinary
• Skin
• Brain/Nervous System
• Sarcoma
• Hematological Malignancies
• Lung
• Head and Neck
• Other Cancer Types

Multicancer Screening Market, By Application

• Clinical
• Research

Multicancer Screening Market, By End User

• Hospitals
• Diagnostic and Clinical Laboratories
• Academic Research Institutions
• Others

Multicancer Screening Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations:

Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
  • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others)
  • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, Others)
  • 5.2.4. By Method (DNA, RNA, Proteins)
  • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types)
  • 5.2.6. By Application (Clinical, Research)
  • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others)
  • 5.2.8. By Region
  • 5.2.9. By Company (2025)
• 5.3. Market Map

6. North America Multicancer Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By Sample
  • 6.2.4. By Method
  • 6.2.5. By Cancer Type
  • 6.2.6. By Application
  • 6.2.7. By End User
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multicancer Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Sample
      • 6.3.1.2.4. By Method
      • 6.3.1.2.5. By Cancer Type
      • 6.3.1.2.6. By Application
      • 6.3.1.2.7. By End User
  • 6.3.2. Canada Multicancer Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Sample
      • 6.3.2.2.4. By Method
      • 6.3.2.2.5. By Cancer Type
      • 6.3.2.2.6. By Application
      • 6.3.2.2.7. By End User
  • 6.3.3. Mexico Multicancer Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Sample
      • 6.3.3.2.4. By Method
      • 6.3.3.2.5. By Cancer Type
      • 6.3.3.2.6. By Application
      • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By Sample
  • 7.2.4. By Method
  • 7.2.5. By Cancer Type
  • 7.2.6. By Application
  • 7.2.7. By End User
  • 7.2.8. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Multicancer Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Sample
      • 7.3.1.2.4. By Method
      • 7.3.1.2.5. By Cancer Type
      • 7.3.1.2.6. By Application
      • 7.3.1.2.7. By End User
  • 7.3.2. France Multicancer Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Sample
      • 7.3.2.2.4. By Method
      • 7.3.2.2.5. By Cancer Type
      • 7.3.2.2.6. By Application
      • 7.3.2.2.7. By End User
  • 7.3.3. United Kingdom Multicancer Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Sample
      • 7.3.3.2.4. By Method
      • 7.3.3.2.5. By Cancer Type
      • 7.3.3.2.6. By Application
      • 7.3.3.2.7. By End User
  • 7.3.4. Italy Multicancer Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Sample
      • 7.3.4.2.4. By Method
      • 7.3.4.2.5. By Cancer Type
      • 7.3.4.2.6. By Application
      • 7.3.4.2.7. By End User
  • 7.3.5. Spain Multicancer Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Sample
      • 7.3.5.2.4. By Method
      • 7.3.5.2.5. By Cancer Type
      • 7.3.5.2.6. By Application
      • 7.3.5.2.7. By End User

8. Asia Pacific Multicancer Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By Sample
  • 8.2.4. By Method
  • 8.2.5. By Cancer Type
  • 8.2.6. By Application
  • 8.2.7. By End User
  • 8.2.8. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Multicancer Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Sample
      • 8.3.1.2.4. By Method
      • 8.3.1.2.5. By Cancer Type
      • 8.3.1.2.6. By Application
      • 8.3.1.2.7. By End User
  • 8.3.2. India Multicancer Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Sample
      • 8.3.2.2.4. By Method
      • 8.3.2.2.5. By Cancer Type
      • 8.3.2.2.6. By Application
      • 8.3.2.2.7. By End User
  • 8.3.3. Japan Multicancer Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Sample
      • 8.3.3.2.4. By Method
      • 8.3.3.2.5. By Cancer Type
      • 8.3.3.2.6. By Application
      • 8.3.3.2.7. By End User
  • 8.3.4. South Korea Multicancer Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Sample
      • 8.3.4.2.4. By Method
      • 8.3.4.2.5. By Cancer Type
      • 8.3.4.2.6. By Application
      • 8.3.4.2.7. By End User
  • 8.3.5. Australia Multicancer Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Sample
      • 8.3.5.2.4. By Method
      • 8.3.5.2.5. By Cancer Type
      • 8.3.5.2.6. By Application
      • 8.3.5.2.7. By End User

9. Middle East & Africa Multicancer Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By Sample
  • 9.2.4. By Method
  • 9.2.5. By Cancer Type
  • 9.2.6. By Application
  • 9.2.7. By End User
  • 9.2.8. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Multicancer Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Sample
      • 9.3.1.2.4. By Method
      • 9.3.1.2.5. By Cancer Type
      • 9.3.1.2.6. By Application
      • 9.3.1.2.7. By End User
  • 9.3.2. UAE Multicancer Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Sample
      • 9.3.2.2.4. By Method
      • 9.3.2.2.5. By Cancer Type
      • 9.3.2.2.6. By Application
      • 9.3.2.2.7. By End User
  • 9.3.3. South Africa Multicancer Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Sample
      • 9.3.3.2.4. By Method
      • 9.3.3.2.5. By Cancer Type
      • 9.3.3.2.6. By Application
      • 9.3.3.2.7. By End User

10. South America Multicancer Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By Sample
  • 10.2.4. By Method
  • 10.2.5. By Cancer Type
  • 10.2.6. By Application
  • 10.2.7. By End User
  • 10.2.8. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Multicancer Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Sample
      • 10.3.1.2.4. By Method
      • 10.3.1.2.5. By Cancer Type
      • 10.3.1.2.6. By Application
      • 10.3.1.2.7. By End User
  • 10.3.2. Colombia Multicancer Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Sample
      • 10.3.2.2.4. By Method
      • 10.3.2.2.5. By Cancer Type
      • 10.3.2.2.6. By Application
      • 10.3.2.2.7. By End User
  • 10.3.3. Argentina Multicancer Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Sample
      • 10.3.3.2.4. By Method
      • 10.3.3.2.5. By Cancer Type
      • 10.3.3.2.6. By Application
      • 10.3.3.2.7. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Multicancer Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Atara Biotherapeutics, Inc.
• 15.3. Burning Rock Biotech Limited
• 15.4. Exact Sciences Corporation
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Fulgent Genetics, Inc.
• 15.7. Genecast Biotechnology Co., Ltd.
• 15.8. Guardant Health, Inc.
• 15.9. Illumina, Inc.
• 15.10. Konica Minolta, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer